Thursday, 15 October 2026European Markets

ROULARTA And POLARIS MEDIA Have A High Dividend Yield And Return On Equity In The Publishing Industry.

Loading stream...

(VIANEWS) - ROULARTA (ROU.BR) is among this list of stock assets with the highest dividend rate and return on equity on the Publishing industry.

Financial Asset Price Forward Dividend Yield Return on Equity
ROULARTA (ROU.BR) €17.20 5.67% 6.38%
POLARIS MEDIA (POL.OL) kr53.60 2.92% 2.05%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ROULARTA (ROU.BR)

5.67% Forward Dividend Yield and 6.38% Return On Equity

Roularta Media Group NV operates as a multimedia company in Belgium, the Netherlands, and Germany. The company operates in two segments, Media Brands and Printing Services. It offers general news, business magazines and sports weeklies, lifestyle magazines, and medical and professional magazines; and local papers, Sunday papers, and internet marketing solutions, as well as operates business television. It also provides recruitment solutions; brand studio; real estate, printing, and business information services; events, fairs, and networking services; line extensions and rights; and advertising services. In addition, the company engages in subscriptions and sales of the newsstand. Roularta Media Group NV was founded in 1954 and is headquartered in Roeselare, Belgium. Roularta Media Group NV is a subsidiary of Koinon Comm.VA.

Earnings Per Share

As for profitability, ROULARTA has a trailing twelve months EPS of €0.48.

PE Ratio

ROULARTA has a trailing twelve months price to earnings ratio of 35.83. Meaning, the purchaser of the share is investing €35.83 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.38%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 19.3%, now sitting on 331.25M for the twelve trailing months.

More news about ROULARTA.

2. POLARIS MEDIA (POL.OL)

2.92% Forward Dividend Yield and 2.05% Return On Equity

Polaris Media ASA operates as a digital media company in Norway and Sweden. The company provides digital advertising services. It also prints corporate and external newspapers, including editorial vouchers, advertising vouchers and newspapers, civil prints, and other magazines/vouchers. In addition, the company distributes newspapers, as well as parcels, mails, and food deliveries. The company is headquartered in Trondheim, Norway.

Earnings Per Share

As for profitability, POLARIS MEDIA has a trailing twelve months EPS of kr1.98.

PE Ratio

POLARIS MEDIA has a trailing twelve months price to earnings ratio of 27.13. Meaning, the purchaser of the share is investing kr27.13 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.05%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on May 4, 2023, the estimated forward annual dividend rate is 1.5 and the estimated forward annual dividend yield is 2.92%.

Yearly Top and Bottom Value

POLARIS MEDIA's stock is valued at kr53.60 at 06:40 EST, way below its 52-week high of kr94.00 and higher than its 52-week low of kr50.00.

Volume

Today's last reported volume for POLARIS MEDIA is 1 which is 99.87% below its average volume of 813.

More news about POLARIS MEDIA.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com